Sun Pharma Advanced Research Company Ltd
₹ 178
-0.56%
29 Mar
- close price
About
Sun Pharma Advanced Research Company Ltd is engaged in the business of research and development (R&D) of pharmaceutical products.[1]
Key Points
- Market Cap ₹ 5,767 Cr.
- Current Price ₹ 178
- High / Low ₹ 309 / 160
- Stock P/E
- Book Value ₹ -4.30
- Dividend Yield 0.00 %
- ROCE %
- ROE %
- Face Value ₹ 1.00
Pros
- Company is expected to give good quarter
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -0.87%
- The company has delivered a poor sales growth of -5.39% over past five years.
- Debtor days have increased from 58.5 to 73.8 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Miscellaneous Industry: Miscellaneous
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
58 | 29 | 87 | 167 | 156 | 161 | 181 | 78 | 183 | 77 | 253 | 137 | 216 | |
65 | 99 | 104 | 134 | 191 | 224 | 304 | 321 | 334 | 387 | 388 | 324 | 407 | |
Operating Profit | -7 | -70 | -17 | 34 | -35 | -63 | -123 | -243 | -151 | -310 | -135 | -187 | -191 |
OPM % | -11% | -241% | -19% | 20% | -23% | -39% | -68% | -310% | -83% | -404% | -53% | -136% | -88% |
1 | 1 | 2 | 10 | 3 | 3 | 14 | 54 | 14 | 10 | 5 | 7 | 0 | |
Interest | 0 | 0 | 4 | 6 | 0 | 2 | 2 | 0 | 0 | 3 | 11 | 13 | 10 |
Depreciation | 3 | 3 | 3 | 4 | 7 | 8 | 8 | 8 | 8 | 9 | 11 | 10 | 11 |
Profit before tax | -8 | -72 | -22 | 34 | -40 | -70 | -119 | -197 | -145 | -312 | -151 | -203 | -212 |
Tax % | 0% | 0% | 0% | 12% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | |
Net Profit | -8 | -72 | -22 | 30 | -40 | -70 | -119 | -197 | -145 | -312 | -151 | -203 | -212 |
EPS in Rs | -0.34 | -2.93 | -0.91 | 1.23 | -1.60 | -2.83 | -4.82 | -7.85 | -5.55 | -11.92 | -5.77 | -7.48 | -7.79 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 17% |
5 Years: | -5% |
3 Years: | -9% |
TTM: | 54% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | -24% |
3 Years: | -15% |
TTM: | -12% |
Stock Price CAGR | |
---|---|
10 Years: | 5% |
5 Years: | -14% |
3 Years: | 23% |
1 Year: | -41% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
Last Year: | % |
Balance Sheet
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Sep 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
21 | 21 | 24 | 24 | 24 | 24 | 25 | 25 | 26 | 26 | 26 | 27 | 27 | |
Reserves | -15 | -87 | 85 | 116 | 76 | 8 | 133 | 160 | 270 | -45 | -194 | -230 | -146 |
7 | 68 | 81 | 5 | 4 | 56 | 3 | 2 | 2 | 67 | 236 | 79 | 193 | |
66 | 84 | 20 | 39 | 39 | 75 | 111 | 122 | 101 | 224 | 162 | 404 | 218 | |
Total Liabilities | 78 | 86 | 209 | 184 | 143 | 163 | 273 | 309 | 398 | 273 | 230 | 280 | 292 |
63 | 64 | 66 | 64 | 67 | 70 | 69 | 52 | 58 | 104 | 91 | 92 | 121 | |
CWIP | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 3 | 24 | 32 | 5 | 26 | 5 |
Investments | 2 | 0 | 97 | 6 | 0 | 0 | 10 | 108 | 211 | 8 | 6 | 12 | 2 |
11 | 21 | 46 | 112 | 76 | 92 | 192 | 146 | 106 | 128 | 127 | 150 | 164 | |
Total Assets | 78 | 86 | 209 | 184 | 143 | 163 | 273 | 309 | 398 | 273 | 230 | 280 | 292 |
Cash Flows
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2 | -69 | -95 | 37 | -41 | -44 | -128 | -183 | -172 | -211 | -152 | -208 | |
-8 | -2 | -99 | 44 | 53 | -13 | -7 | -105 | -102 | 155 | 2 | -29 | |
4 | 72 | 194 | -81 | -1 | 51 | 194 | 224 | 274 | 55 | 159 | 229 | |
Net Cash Flow | -1 | 0 | -0 | -0 | 11 | -7 | 60 | -63 | 0 | 0 | 9 | -8 |
Ratios
Figures in Rs. Crores
Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 16 | 54 | 105 | 61 | 47 | 21 | 78 | 82 | 20 | 76 | 25 | 74 |
Inventory Days | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
Days Payable | ||||||||||||
Cash Conversion Cycle | 16 | 54 | 105 | 61 | 47 | 21 | 78 | 82 | 20 | 76 | 25 | 74 |
Working Capital Days | -372 | -899 | 72 | 129 | 21 | -42 | -59 | -232 | -98 | -557 | -96 | -97 |
ROCE % | -59% | -1,034% | -20% | 21% | -32% | -71% | -94% | -143% | -62% | -183% | -242% |
Documents
Announcements
- IT Security Incident 2d
-
Clarification - Increase In Volume
24 Mar - Reply to email clarification dated March 24, 2023
-
Clarification sought from Sun Pharma Advanced Research Company Ltd
24 Mar - Exchange has sought clarification from Sun Pharma Advanced Research Company Ltd on March 24, 2023, with reference to Movement in Volume.
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 14 Mar
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 10 Mar
Annual reports
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2011
from nse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Revenue Sources
The company is a clinical stage bio-pharmaceutical company and earns its revenues from license fee/ royalty on technology and R&D services.[1]